Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
10/24/2008
Trade Name:
Apidra
Generic or Proper Name (*):
insulin glulisine recombinant
Indications Studied:
Diabetes Mellitus
Therapeutic Category:
Antidiabetic
Ages Studied:
4-17 years
Study #:
2
Study Type:
Safety/Pharmacokinetic/Pharmacodynamic
Study Design:
Single-Blind/Traditional Pharmacokinetic/Crossover
No Patients:
20
No Centers:
1
No Countries:
1
BPCA(B), PREA(P):
P
-
-